Standard Biotools is trading 9.18% up in pre-market at $0.71, versus its October 21 close of $0.65; no clear company-specific catalyst has been identified. - The investor-relations release list shows no announcement dated October 22; its latest listed release is the October 5 agreement to sell its Microfluidics business. - The broader market context is negative and does not explain the upward move; the reason remains unclear.